Payment overview · 2025
General Payments
$409.73
4 reported records · 3 companies
Healthcare provider profile · identity verified
Patrick J Cullen, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · NORWICH, CT · NPI 1679556856
Verified facts
What the public records show
CMS Open Payments records show Patrick J Cullen, PA-C received $409.73 in general payments during 2025 across 4 reported records.
Abbott Laboratories accounted for 70.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $290.49 | 70.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.87 | 22.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.37 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $409.73 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $165.90 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $124.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $90.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 76 |
| Gabapentin | Gabapentin | 316 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 59 |
| Oxycodone Hcl | Oxycodone Hcl | 211 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 35 |
| Metformin Hcl | Metformin Hcl | 160 | 39 |
| Losartan Potassium | Losartan Potassium | 151 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 148 | 24 |
| Omeprazole | Omeprazole | 143 | 26 |
| Montelukast Sodium | Montelukast Sodium | 137 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 30 |
| Tramadol Hcl | Tramadol Hcl | 134 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 31 |
| Pregabalin | Pregabalin | 119 | 27 |
| Lisinopril | Lisinopril | 118 | 33 |
| Furosemide | Furosemide | 116 | 30 |
| Ozempic | Semaglutide | 116 | 19 |
| Famotidine | Famotidine | 107 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 18 |
| Sertraline Hcl | Sertraline Hcl | 107 | 22 |
| Ibuprofen | Ibuprofen | 106 | 21 |
| Jardiance | Empagliflozin | 89 | 17 |
| Celecoxib | Celecoxib | 88 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 84 | 24 |
| Trazodone Hcl | Trazodone Hcl | 84 | 25 |
| Baclofen | Baclofen | 81 | 15 |
| Carvedilol | Carvedilol | 77 | 15 |
| Eliquis | Apixaban | 74 | 15 |
| Tradjenta | Linagliptin | 74 | suppressed |
| Clonazepam | Clonazepam | 72 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 20 |
| Buspirone Hcl | Buspirone Hcl | 69 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 66 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 59 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 15 |
| Azelastine Hcl | Azelastine Hcl | 53 | 25 |
| Prednisone | Prednisone | 52 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Potassium Chloride | Potassium Chloride | 51 | 16 |
| Alprazolam | Alprazolam | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 41 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Simvastatin | Simvastatin | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 12 |
| Methylprednisolone | Methylprednisolone | 38 | 28 |
| Naproxen | Naproxen | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 14 |
| Linzess | Linaclotide | 35 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Meclizine Hcl | Meclizine Hcl | 33 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | 11 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Lidocaine | Lidocaine | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Glipizide | Glipizide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 11 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Mupirocin | Mupirocin | 17 | 11 |
| Topiramate | Topiramate | 17 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Fioricet | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $409.73 · 4 records | Abbott Laboratories | AVEIR, Cologuard Collection Kit, PERCLOSE PROSTYLE, VOQUEZNA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error